for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

XBiotech Inc

XBIT.OQ

Latest Trade

9.62USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.54

 - 

11.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.62
Open
--
Volume
--
3M AVG Volume
3.37
Today's High
--
Today's Low
--
52 Week High
11.70
52 Week Low
2.54
Shares Out (MIL)
41.01
Market Cap (MIL)
394.12
Forward P/E
-15.50
Dividend (Yield %)
--

Next Event

Q3 2019 XBiotech Inc Earnings Release

Latest Developments

More

XBiotech Says Public Offering Of 4.85 Million Common Shares Priced At $8.25 Per Share

XBiotech Says Public Offering Of 4.85 Million Common Shares Priced At $8.25 Per Share

Xbiotech Announces Public Offering Of Common Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About XBiotech Inc

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Industry

Biotechnology & Drugs

Contact Info

Building 4, 8201 E Riverside Dr Ste 100

+1.512.3862930

Executive Leadership

John Simard

Chairman of the Board, President, Chief Executive Officer, Founder

Scott Whitehurst

Chief Financial Officer

Kelly R. Thornburg

Senior Vice President - Operations

Queena Clark Han

Vice President - Finance, Human Resources

David J Combs

Vice President - Manufacturing

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019(E)

0.0K
EPS (USD)

2016

-1.630

2019(E)

-0.620
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-37.83
Return on Equity (TTM)
-36.27

Latest News

BRIEF-XBiotech Announces First Patient In Phase 2 Study Evaluating Patients With Atopic Dermatitis

* XBIOTECH ANNOUNCES FIRST PATIENT IN PHASE 2 STUDY EVALUATING MABP1 IN PATIENTS WITH ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

BRIEF-XBiotech In-Licenses Anti-NY-ESO 1 Antibody Targeting Advanced Cancer

* HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG Source text for Eikon: Further company coverage:

BRIEF-XBIOTECH ‍ENROLLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN WITH ONIVYDE

* ENROLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN COMBINATION WITH ONIVYDE & 5-FLUOROURACIL/FOLINIC ACID FOR TREATMENT OF PANCREATIC CANCER Source text for Eikon: Further company coverage:

BRIEF-XBiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 combination for the treatment of pancreatic cancer

* Xbiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 in combination with Onivyde and 5-fluorouracil/folinic acid for the treatment of pancreatic cancer Source text for Eikon: Further company coverage:

BRIEF-XBiotech - European Medicines Agency maintains its May 18, 2017 opinion

* XBiotech - on Sept 14, although there were advancements in certain areas of application European Medicines Agency has maintained its May 18, 2017 opinion

BRIEF-XBiotech announces discontinuation of phase III study for colorectal cancer based on second interim analysis

* XBiotech announces discontinuation of phase III study for colorectal cancer based on second interim analysis

BRIEF-Xbiotech says received negative opinion for its lead product candidate in Europe

* Xbiotech - received negative opinion from EMA CHMP for marketing authorization application for its lead product candidate in Europe

BRIEF-Xbiotech reports outcome of EMA's oral explanation meeting

* Xbiotech announces outcome of ema's oral explanation meeting

BRIEF-XBiotech announces top-line results for 514G3 antibody therapy in serious staphylococcus aureus infections

* XBiotech announces top-line results for 514G3 antibody therapy in serious staphylococcus aureus infections

BRIEF-XBiotech announces on-time submission to the EMA

* Xbiotech - completed on time and confirmed receipt of its march 22, 2017 submission of responses to remaining ema queries related to its maa Source text for Eikon: Further company coverage:

BRIEF-Xbiotech announces registered direct offering of common shares

* Xbiotech announces registered direct offering of common shares

BRIEF-XBIOTECH MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY OF MABP1 FOR TREATMENT OF HIDRADENITIS SUPPURATIVA

* XBIOTECH MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY OF MABP1 FOR TREATMENT OF HIDRADENITIS SUPPURATIVA (HS)

BRIEF-Xbiotech announces dismissal of class action lawsuit in Texas

* Xbiotech announces dismissal of class action lawsuit in Texas

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up